Obsidian Therapeutics
1030 Massachusetts Avenue
Cambridge
Massachusetts
02138
United States
Tel: (781) 806-6245
Website: https://obsidiantx.com/
Email: info@obsidiantx.com
About Obsidian Therapeutics
Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy.
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.
Located in the heart of Cambridge, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options. Apply to jobs@obsidiantx.com.
26 articles with Obsidian Therapeutics
-
Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the 24th American Society of Gene and Cell Therapy Annual Meeting
5/4/2021
Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present at the upcoming 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021.
-
Per BioSpace’s 2020 U.S. Life Sciences Salary Report and 2020 U.S. Life Sciences Diversity & Inclusion Report, men out-earn women by 19.3%, which climbs to 47.6% when looking specifically at health care. Also, only 14% of women felt that opportunities for promotion were fair compared to 23% of th...
-
Despite a historic push for greater diversity and inclusion (D&I), a significant disconnect prevails between good intentions and actual lived experiences.
-
In the run-up to January’s JP Morgan Healthcare Conference, BioSpace caught up with CEO Paul Wotton to discuss the company’s plans for 2021. More collaborations are key features.
-
Obsidian Therapeutics Appoints Jan ter Meulen, M.D., Ph.D., as Chief Scientific Officer
9/17/2020
Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Jan Henrik ter Meulen, M.D., Ph.D. , has been appointed Chief Scientific Officer. Dr. ter Meulen will lead Obsidian's ongoing efforts in the application of the Company's proprietary cytoDRiVE ™ platfor
-
Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate
9/15/2020
Obsidian Therapeutics , Inc. , a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the i
-
Obsidian Therapeutics Appoints Rob Ross, M.D., to Board of Directors
9/3/2020
Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Robert Ross , M.D., to its Board of Directors. Dr. Ross currently s
-
Obsidian Therapeutics Develops and Shares Safe Workplace Productivity Solution in Response to COVID19
5/1/2020
Implementation has enabled Obsidian to remain on track to meet development targets, while maintaining a safe working environment for all employees
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
-
Obsidian Therapeutics Appoints Anders Götzsche to Board of Directors
3/3/2020
Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Anders Götzsche to its Board of Directors
-
Obsidian Therapeutics Announces Formation of Scientific Advisory Board
2/5/2020
Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, announced the formation of its Scientific Advisory Board (SAB).
-
Obsidian Therapeutics Announces Expansion of Leadership Team
11/12/2019
Additions support Obsidian's active program development, operational build-out and ongoing regulatory discussions
-
Obsidian Therapeutics Appoints Erin Boyer as Vice President, Human Resources
9/24/2019
Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Erin Boyer as Vice President, Human Resources
-
What if you could more precisely control CAR-T cells using FDA-approved small molecules to enhance their activity against solid tumors? That’s exactly what Obsidian Therapeutics is aiming to do.
-
BioSpace Movers and Shakers, July 26
7/26/2019
Biotech and pharma companies bolster their executive leadership and boards of directors with this week's appointments. -
Obsidian Therapeutics Announces Strengthening of Executive Leadership Team
7/25/2019
Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced executive management appointments that organizationally support the Company's long-term strategy.
-
BioSpace Movers and Shakers: April 19
4/19/2019
Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more. -
Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer
4/18/2019
Experienced CEO brings expertise in product development, cell and gene therapies, and public biotechnology companies as Obsidian positions itself for future growth
-
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings
1/18/2019
Companies enter into multi-year strategic collaboration with Celgene receiving exclusive options to license cell therapies that utilize Obsidian’s Destabilizing Domain technology to modulate IL12 and CD40L activity
-
Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.